A molecular diagnostic panel for infectious diarrhea is a multiplex nucleic acid amplification test (NAAT) that simultaneously detects and differentiates DNA or RNA from multiple bacterial, viral, and parasitic pathogens in a single stool sample. Such panels often include targets for Giardia lamblia, Cryptosporidium spp., Entamoeba histolytica, and sometimes Dientamoeba fragilis, alongside common bacterial (Campylobacter, Salmonella, Shigella, E. coli) and viral (Norovirus, Rotavirus) agents. Advantages over traditional methods (microscopy, culture, individual antigen tests) are substantial: 1) Higher Sensitivity and Specificity: NAATs can detect low pathogen loads and identify organisms like D. fragilis or Entamoeba dispar/histolytica specifically. 2) Rapid Turnaround: Results in hours vs. days for culture. 3) Comprehensive Testing: A single test replaces multiple procedures, streamlining workflow. 4) Detection of Co-infections: Identifies multiple pathogens, which is common in some settings. For patient management, this leads to faster, more accurate diagnosis, allowing targeted therapy (e.g., metronidazole for Giardia, not antibiotics for a virus), reducing unnecessary antibiotic use, and enabling appropriate infection control measures. Limitations include: 1) Cost: Panels are expensive. 2) Detection of DNA/RNA, not necessarily viable organisms, which could lead to over-treatment of past infections. 3) May miss novel or rare pathogens not included in the panel. 4) Requires specific equipment and technical expertise. 5) Does not provide parasite burden or drug sensitivity information. Despite limitations, such panels represent a major advance in diagnostic efficiency.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Joseph Soko – 101 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies